|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Nurix Therapeutics, Inc. (NRIX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
15,218 |
35,430 |
43,924 |
56,372 |
| Total Sell Value |
$172,193 |
$362,771 |
$427,193 |
$583,289 |
| Total People Sold |
3 |
3 |
3 |
4 |
| Total Sell Transactions |
5 |
10 |
16 |
32 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wolff Stefani |
EVP and COO |
• – – |
2023-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
962 |
6,455 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2023-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,924 |
10,722 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,886 |
79,651 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,206 |
27,768 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2023-01-30 |
4 |
S |
$11.78 |
$9,989 |
D/D |
(848) |
7,261 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2023-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,924 |
8,109 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-01-30 |
4 |
S |
$11.78 |
$16,633 |
D/D |
(1,412) |
23,009 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,207 |
24,421 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2023-01-30 |
4 |
S |
$11.78 |
$4,995 |
D/D |
(424) |
3,940 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2023-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
962 |
4,364 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-01-30 |
4 |
S |
$11.78 |
$10,884 |
D/D |
(924) |
76,765 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,886 |
77,689 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2022-10-31 |
4 |
S |
$12.88 |
$9,003 |
D/D |
(699) |
6,185 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2022-10-31 |
4 |
S |
$12.88 |
$9,519 |
D/D |
(739) |
74,803 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2022-10-31 |
4 |
S |
$12.88 |
$4,508 |
D/D |
(350) |
3,402 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-10-31 |
4 |
S |
$12.88 |
$15,006 |
D/D |
(1,165) |
21,214 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2022-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,924 |
6,884 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2022-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,886 |
75,542 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2022-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
962 |
3,752 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,207 |
22,379 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-08-01 |
4 |
S |
$15.67 |
$18,585 |
D/D |
(1,186) |
19,172 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2022-08-01 |
4 |
S |
$15.67 |
$5,579 |
D/D |
(356) |
1,238 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2022-08-01 |
4 |
S |
$15.67 |
$11,784 |
D/D |
(752) |
72,656 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2022-08-01 |
4 |
S |
$15.67 |
$11,157 |
D/D |
(712) |
4,615 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-07-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,207 |
20,358 |
|
- |
|
166 Records found
|
|
Page 2 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
